CNTB Connect Biopharma Holdings Limi
$0.85▲ +10.75%
Healthcare
Other
Pre-market
$0.85▲ +0.16%
Oct 27, 7:39 AM ET
Volume 1.75M
Avg Volume (10D) 1.11M
Key Metrics & Fundamentals
Market Cap
$53.46M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.73 - 3.82
% vs 50 MA
-42.86%
% vs 200 MA
-61.77%
RSI-14
35.5
MACD Histogram
+0.0300
Beta (1Y vs SPY)
0.50
Free Cash Flow
-$15.92M
Gross Rev
$2.77M
Gross Profit
$2.77M
EBITDA
-$17.44M
COGS
–
Operating Exp
$20.37M
Operating Income
-$17.60M
EBIT
-$17.60M
Pretax Income
-$17.22M
Net Income
-$17.28M
EPS (Diluted)
-0.27
Price & Volume History
Loading chart…
Recent News
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Zacks · Oct 22, 2026 8:35 AM ET
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Zacks · Oct 19, 2026 8:55 AM ET
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
MarketBeat · Oct 4, 2026 3:02 AM ET
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
InvestorsHub · Sep 30, 2026 10:43 AM ET
BC-Most Active Stocks
Associated Press · Sep 30, 2026 10:30 AM ET
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
GlobeNewswire · Sep 30, 2026 7:00 AM ET
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
Insider Monkey · Sep 22, 2026 7:45 PM ET
Oppenheimer Adjusts Price Target on Connect Biopharma to $5 From $8, Keeps Outperform Rating
MT Newswires · Sep 22, 2026 8:50 AM ET
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
InvestorsHub · Sep 15, 2026 11:01 AM ET
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
GlobeNewswire · Sep 15, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CNTB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.